Blockade of ROS production inhibits oncogenic signaling in acute myeloid leukemia and amplifies response to precision therapies

- Germon, Zacary P., Sillar, Jonathan R., McLachlan, Tabitha, Schjenken, John E., Skerrett-Byrne, David A., Huang, Honggang, Melo-Braga, Marcella N., Plank, Maximillan W., Alvaro, Frank, Chamberlain, Janis, De Iuliis, Geoff, Aitken, R. John, Mannan, Abdul, Nixon, Brett, Wei, AH, Enjeti, Anoop K., Huang, Y, Lock, RB, Larsen, MR, Lee, Heather, Vaghjiani, V, Cain, JE, de Bock, CE, Duchatel, Ryan J., Verrills, Nicole M., Dun, Matthew D., Staudt, Dilana, Murray, Heather C., Findlay, Izac J., Jackson, Evangeline R., McEwen, Holly P., Douglas, Alicia M.

Preclinical and clinical evaluation of German-sourced ONC201 for the treatment of H3K27M-mutant diffuse intrinsic pontine glioma

- Duchatel, Ryan J., Mannan, Abdul, Kearney, Padraic S., Smith, Nathan D., Hindley, Kate E., Cain, Jason E., André, Nicolas, La Madrid, Andres Morales, Nixon, Brett, De Iuliis, Geoffry N., Nazarian, Javad, Irish, Kathleen, Woldu, Ameha S., Alvaro, Frank, Eisenstat, DD, Beck, A, Vitanza, NA, Mueller, S, Morris, JC, Dun, Matthew D., Hawtrey, Tom, Hindley, Phoebe A., Douglas, Alicia M., Jackson, Evangeline R., Findlay, Izac J., Germon, Zacary P., Staudt, Dilana

Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance

- Staudt, Dilana, Murray, Heather C., McLachlan, Tabitha, Alvaro, Frank, Enjeti, Anoop K., Verrills, Nicole M., Dun, Matthew D.